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Hypertensive disorders of pregnancy (HDP) have been associated with heart failure (HF). It is 
unknown whether concurrent pregnancy complications (small-for-gestational age [SGA] or 
preterm delivery) or recurrent HDP modify HDP-associated HF risk. In this cohort study, we 
included Norwegian women with a first birth between 1980-2004. Follow-up occurred through 
2009. Cox models examined gestational hypertension (GH) and preeclampsia in the first 
pregnancy as predictors of a composite of HF-related hospitalization or HF-related death, with 
assessment of effect modification by concurrent SGA and/or preterm delivery. Additional 
models were stratified by final parity (1 vs. 2 births) and tested associations with recurrent 
HDP. Among 508,422 women, 565 experienced incident HF over a median 11.8 years of follow-
up. After multivariable adjustment, GH in the first birth was not significantly associated with HF 
(hazard ratio [HR] 1.41, 95% CI 0.84-2.35, P=0.19), whereas preeclampsia was associated with 
an HR of 2.00 (95% CI 1.50-2.68, P<0.001). Among women with HDP, risks were not modified 
by concurrent SGA and/or preterm delivery (Pinteraction = 0.42). Largest hazards of HF were 
observed in women whose only lifetime birth was complicated by preeclampsia and women with 
recurrent preeclampsia. HF risks were similar after excluding women with coronary artery 
disease. In summary, women with preeclampsia, especially those with one lifetime birth and 
those with recurrent preeclampsia, experienced increased HF risk compared to women without 
HDP. Further research is needed to clarify causal mechanisms. 
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 Hypertensive disorders of pregnancy (HDP, i.e., gestational hypertension [GH]; 
preeclampsia; eclampsia; and hemolysis, elevated liver enzymes, and low platelet [HELLP] 
syndrome) affect 5-10% of pregnancies worldwide.1,2 HDP are associated with a roughly two-
fold increase in future maternal cardiovascular disease risk.3-6 Cardiovascular risks associated 
with HDP are best described for atherosclerotic cardiovascular disease (ASCVD, e.g., coronary 
artery disease [CAD] and ischemic stroke) but extend beyond ASCVD to include heart failure 
(HF) and cardiomyopathy.5,7-9 Although HDP are associated with peripartum cardiomyopathy,10 
HDP may also be associated with long-term HF risk separate from peripartum cardiomyopathy.9  
 Other pregnancy complications, such as small-for-gestational age (SGA) and preterm 
delivery, are independently associated with increased future maternal ASCVD disease risk11-13 
and modify ASCVD risk when they accompany HDP.13 In addition, ASCVD risks associated 
with recurrent HDP are greater than those associated with single-episode HDP.13,14 However, 
whether concurrent pregnancy complications (SGA and preterm delivery) or recurrent HDP also 
modify HF risk among women with HDP remains unclear. Understanding the contribution of 
concurrent pregnancy complications to the HDP-associated HF risk distribution may help with 
clinical risk stratification and may yield insights regarding mechanisms of HDP-associated HF. 
 To better characterize HF risk in women with GH and preeclampsia, we studied HF 
incidence in a large nationwide cohort of Norwegian women. We hypothesized (1) that HDP 
would be associated with long-term HF risk, (2) that concurrent SGA and/or preterm delivery 
would further increase risk compared with HDP alone, and (3) that recurrent HDP would be 




















    
    
    
    
    













 Researchers may apply for permission to analyze data from the Cardiovascular Disease in 
Norway Project (CVDNOR) at www.cvdnor.no. Women with a first birth between 1980-2004 
recorded in the Medical Birth Registry of Norway (MBRN) who were 16-49 years old at the first 
birth and had 5 a  prior to 2010 were considered for inclusion. The MBRN is a 
nationwide Norwegian registry with mandatory reporting, capturing all pregnancies since 1967 
a  16  a  or more.15 To ascertain incident cardiovascular diagnoses, MBRN 
records were linked to the CVDNOR, a database containing inpatient diagnosis codes from all 
hospitalizations in Norway from 1994 onward, and to the Norwegian Cause of Death Registry. 
The Norwegian Regional Committee for Medical and Health Research Ethics and the Partners 
HealthCare institutional review board approved these analyses.  
Women with pre-gestational chronic hypertension registered in the MBRN or with 
established cardiovascular disease (defined as International Classification of Diseases [ICD]-10 
codes I00-I99, ICD-9 450-454 and 456-459, and ICD-8 390-448) identified in CVDNOR prior to 
the first birth were excluded, as were women with extreme birthweight outliers (Z-score >4 or  
<-4) in the first birth, multiple gestation in the first birth, missing data on gestational duration or 
birth weight in the first birth, a  b     20  a . To capture each 
a   e career, women with a first birth after 2004 were excluded, and follow-
up began at the last birth; we therefore also excluded women who developed HF prior to the last 




















    
    
    
    
    











 GH and preeclampsia in the first pregnancy constituted the primary exposures, with 
assessment of effect modification by concurrent SGA and/or preterm delivery. (Most HDP cases 
occur in the first pregnancy.16) In primary analyses, women without HDP in the first pregnancy 
served as the reference group. I  a a    HDP,   2  b  a  
normotension in all pregnancies constituted the reference group.  
The MBRN defines GH a   a  b   a  20  a   
 b   140  H  and/  a  b   90  H , without 
proteinuria. The MBRN defines preeclampsia as newly elevated blood pressure, using the same 
blood pressure criteria, accompanied by proteinuria >0.3 g/24 h or >1+ on urine dipstick, with 
high positive predictive value demonstrated in validation studies.17,18 Preterm delivery was 
defined as delive   b  37  a . SGA a   a  a   
below the 10th percentile of the Norwegian birth weight curve.19 
 CAD was incorporated as an exclusion in sensitivity analyses. CAD was defined as 
hospitalization or death from CAD as indicated by ICD-9 codes 410-414 and ICD-10 codes I20-
I25, as in previous CVDNOR analyses.13 
Outcome 
 The study outcome was a composite of HF-related hospitalization or death with HF as an 
underlying, contributing, or associated cause. HF cases were identified in CVDNOR20,21 and in 
the Norwegian Cause of Death Registry using ICD-9 codes 425.4 and 428.0-428.9 and using 
ICD-10 codes I42.0, I42.8, I42.9, I50.1-I50.4, and I50.9, encompassing both HF with reduced 
ejection fraction and HF with preserved ejection fraction.  



















    
    
    
    
    











The population attributable risk percent (i.e., the percent of HF cases in the cohort 
attributable to HDP) was calculated as the difference in absolute HF incidence in the overall 
study cohort vs. women without HDP divided by overall HF incidence. The attributable 
proportion of HF risk in women with HDP was calculated as the difference in absolute HF risk in 
women with vs. without HDP divided by absolute risk in women with HDP.  
Cox proportional hazard models tested the association of HDP with incident HF. Follow-
up began at the last birth in all models. Censoring occurred at the first HF hospitalization, death, 
or the end of the study period (December 31, 2009), whichever occurred first. Primary models 
were adjusted for maternal birth year (to capture period effects), maternal age at first birth, 
maternal age at last birth, chronic diabetes status at the time of the last birth, and final parity. To 
calculate associations with overall HDP and with HDP subtypes, separate models were run for 
all HDP vs. no HDP (reference) and for gestational hypertension vs. preeclampsia vs. no HDP 
(reference). To test effect modification by concurrent SGA and/or preterm delivery, models 
incorporated an interaction term between SGA and/or preterm delivery and HDP status. In 
addition, because prior data suggested HDP-associated cardiovascular mortality risk is highest 
among women with only o e life-  b  ( -  ),22 we also stratified models by 
a final parity of 1 vs. 2 births; in stratified models, women with multiple normotensive 
pregnancies served as the reference group.  
T  a  HF     a a    a ,   
women into 10 categories according to HDP status in the first birth (no HDP, GH, or 
preeclampsia) and HDP status in the second and all later births (all normotensive, HDP in at least 
one birth, or no later births), adapting the approach used by Tanz et al.11 Additional Cox models 



















    
    
    
    
    











CAD is known to be associated with both HDP and HF. To test whether HDP is 
associated with HF independent of CAD risk, sensitivity analyses excluded women who 
developed CAD during the study period. 
The proportional hazards assumption was tested using Schoenfeld residuals. Two-sided 
P-values <0.05 were considered statistically significant. Analyses were performed using Stata 




 After exclusions, the final study cohort included 508,422 women (Figure 1). There were 
no missing data in the final cohort. Participant counts by the number of lifetime episodes of GH 
and preeclampsia are summarized in Table S1.  
A total of 46,084 women (9.1%) experienced HDP in any pregnancy, of whom 8,827 
women (1.7% of the overall cohort) experienced GH in the first birth and 24,326 (4.8% of the 
overall cohort) experienced preeclampsia in the first birth (Table 1). Women with GH and 
especially those with preeclampsia were more likely than women without HDP to experience 
SGA and/or preterm delivery in the first birth (Table 1).  
Hypertension in the first pregnancy and incident heart failure 
We first assessed whether HDP in the first pregnancy associated with incident HF in our 
cohort. The primary endpoint of HF-related hospitalization or HF-related death occurred in 565 
women (Table 1) over a median follow-up of 11.8 (interquartile range 6.4-17.8) years. The 
primary endpoint occurred in 499 women without HDP in the first pregnancy (0.10%, incidence 



















    
    
    
    
    











women with GH in the first pregnancy (0.17%, incidence rate 13.05/10,000 woman-years of 
follow-up [95% CI 7.96-20.44/10,000 woman-years], incidence rate difference +4.57/10,000 
woman-years vs. women without HDP, P=0.06), and 51 women with preeclampsia in the first 
pregnancy (0.21%, incidence rate 17.90/10,000 woman-years [95% CI 13.63-23.13/10,000 
woman-years], incidence rate difference +9.42/10,000 woman-years vs. women without HDP, 
P<0.001). Of incident HF diagnoses, 540 (95.6%) occurred >6 months after the last birth. Of 565 
incident HF cases, 100 (17.7%) occurred in women with HDP, and the population risk 
attributable to HDP was 9.5%. Among women with HDP, the proportion of incident HF risk 
attributable to HDP was 53.7%. 
In time-to-event models comparing women with vs. without any HDP in the first 
pregnancy and adjusted only for maternal age at the last birth, HDP in the first pregnancy was 
associated with 1.92-fold risk of incident HF (95% CI 1.49-2.48, P<0.001) (Table 2). In fully 
adjusted models, HDP remained significantly associated with HF (HR 1.83, 95% CI 1.41-2.36, 
P<0.001). GH was associated with an HR of 1.41 (95% CI 0.84-2.35, P=0.19) and preeclampsia 
with an HR of 2.00 (95% CI 1.50-2.68, P<0.001) (Figure 2). In multivariable models 
additionally incorporating SGA and preterm delivery as predictors in addition to HDP status, 
SGA delivery was independently associated with incident HF (HR 1.35, 95% CI 1.09-1.67, 
P=0.006) whereas preterm delivery was not (HR 1.26, 95% CI 0.93-1.70, P=0.13).  
Having demonstrated an association between HDP and incident HF, we next tested 
whether concurrent pregnancy complications modified HF risk. HF risk after HDP in the first 
birth was not significantly modified by concurrent SGA and/or preterm delivery (Pinteraction = 
0.42). There was no significant interaction of GH (Pinteraction = 0.81) or preeclampsia (Pinteraction = 



















    
    
    
    
    











Coronary artery disease and incident heart failure risk 
To test whether CAD explained the observed associations between HDP and HF, we 
conducted a sensitivity analyses that excluded women with CAD. Among 565 women with 
incident HF during the study period, 155 (27.4%) also developed CAD. After excluding 2,428 
women from the overall cohort with incident CAD, observed hazards for incident HF were 
similar to the primary analysis (for GH, HR 1.32, 95% CI 0.70-2.48, P=0.39; for preeclampsia, 
HR 1.89, 95% CI 1.33-2.70, P<0.001). 
Differential heart failure risk in women with 1 vs. multiple children 
 We next a  HF  a a   HDP    1 . 2 . 
C a     2 b  and normotension in all pregnancies, women with 1 lifetime 
birth had increased risk of HF irrespective of HDP status but especially if they experienced HDP. 
Among women with HDP, risk of HF was greater among women with 1  b  . 2 
lifetime births (Table S2). Women with HDP in the first birth who subsequently experienced 
only normotensive pregnancies had attenuated HF risk compared to other subgroups of women 
with HDP (Table 3). Notably, elevated HF risks were observed among women with HDP in a 
second and/or later birth even when the first birth was normotensive (for GH in a second and/or 
later birth, HR 3.15, 95% CI 1.77-5.61, P<0.001; for preeclampsia in a second and/or later birth, 
HR 2.92, 95% CI 1.89-4.50, P<0.001). 
Heart failure risk in women with recurrent hypertension in pregnancy 
 Finally, we compared HF risks among women with recurrent HDP, women with one 
lifetime birth, and multiparous women with normotension in all pregnancies. Women with 
preeclampsia in the first birth and HDP in a subsequent birth had similarly elevated HF risk 



















    
    
    
    
    











associated with recurrent HDP was driven predominantly by recurrent preeclampsia (Figure 3, 
Table S3), with a progressive increase in HF incidence rate was observed with increasing 
number of preeclampsia episodes (Ptrend <0.001). Compared to women without preeclampsia 
(irrespective of GH status), single-episode preeclampsia was associated with an HR of 1.93 (95% 
CI 1.47-2.55, P<0.001), and recurrent preeclampsia was associated with an HR of 4.36 (95% CI 
2.71-7.02, P<0.001) for HF (Table S4). After excluding 2,428 women with incident CAD during 
the study period, these associations with HF were only mildly attenuated (for single-episode 




 In a large, nationwide study of Norwegian women followed for a median 12 years after 
the last birth, we observed a two-fold risk of incident HF in women with a history of 
preeclampsia. Contrary to our hypothesis, concurrent SGA and/or preterm delivery did not 
appear to modify HF risks among women with HDP. However, women with preeclampsia in 
their only lifetime birth, as well as women with more than 1 birth who experienced recurrent 
preeclampsia, demonstrated further increases in HF risk. Although HDP is associated with 
incident CAD and CAD is in turn associated with HF, HF risks associated with HDP in our 
cohort appeared largely independent of CAD. In this relatively young cohort of women, absolute 
risks of HF were expectedly low, but a disproportionate number of incident HF cases (17.7%) 
occurred in the 9.1% of women with prior HDP. 
The results of the present study align with prior evidence that preeclampsia-associated 



















    
    
    
    
    











finding to HF. A similar pattern of risk concentration among one-child mothers has also been 
shown with respect to ASCVD risk after preterm delivery.11 Although greater parity, especially 
extreme parity, has been associated with elevated cardiovascular disease risk,23 studies have 
suggested a J-shaped relationship between parity and cardiovascular risk.24-26 The causes of 
HDP-associated risk concentration among women whose only birth is hypertensive are currently 
unknown but may reflect avoidance of additional pregnancies and/or impaired fertility related to 
accelerated development of comorbidities in women with more severe HDP, as well as 
unmeasured socioeconomic factors; further research to clarify mechanisms is needed.  
A    2  b , e observed greater HF risk among women with 
HDP in a second and/or later birth compared to women who experienced HDP only in a first 
birth and normotension in subsequent pregnancies. HDP occurring in a second or subsequent 
birth a a  a  , b    4.7%       2 
lifetime births may serve as an especially important cardiovascular risk signal and warrants 
assessment across other cardiovascular conditions and in other cohorts. 
 Beyond strengthening evidence of an association between HDP and HF, this  
findings may have other implications for understanding long-term cardiovascular risk after HDP. 
First, among women with preeclampsia, we did not observe evidence of effect modification for 
HF risk by concurrent SGA and/or preterm delivery, despite the fact that SGA was an 
independent predictor of HF. Similarly, a prior analysis observed similar hazards for HF in 
women with term and preterm preeclampsia.9 By contrast, further elevation in ASCVD risk 
among women with HDP and SGA and/or preterm delivery has now been well described.4,6,13,27 
This discrepancy suggests that the mechanisms underlying ASCVD and HF after HDP may be 



















    
    
    
    
    











finding from Behrens et al.9 that a significant portion of HF following HDP is non-ischemic, 
even though HDP is also associated with development of CAD. In a previous study of women 
followed prospectively from midlife (mean age 57 years), those with a history of HDP had 
persistently elevated risk of incident HF, and HDP-associated HF risk appeared additive to CAD-
associated HF risk.7 It is likely that the relative contribution of ischemic heart disease to HF risk 
increases in women with HDP with increasing age as ASCVD risk increases with age in the 
population overall. In our younger cohort, however, only one-quarter of women with incident HF 
also had CAD, and exclusion of women with CAD did not meaningfully change the observed 
risks of HF. Further, most HF after HDP (>95%) occurred >6 months after the first birth, 
reinforcing that the vast majority of HF in this population is not peripartum cardiomyopathy.10  
 Second, our results support and extend the limited prior literature on cardiovascular 
disease risk after recurrent HDP27,28 by demonstrating greater HF risk following recurrent 
preeclampsia compared with single-episode preeclampsia. Prior work suggested further increase 
in HF risk after recurrent vs. single-episode preeclampsia,28 but this analysis only tested risk 
differences among women with multiple births and did not test the influence of comorbid CAD. 
In the present analysis, we observed these associations even among women without CAD, 
despite the dose-dependent relationship shown previously between recurrent preeclampsia and 
CAD.6,13,14 Taken together with prior literature, our findings identify women with recurrent 
preeclampsia and women with a single lifetime birth complicated by preeclampsia as highest-risk 
for both ASCVD and non-ASCVD cardiovascular disease within the spectrum of HDP-
associated risk. Further investigation is needed to disentangle whether HF risk associated with 



















    
    
    
    
    











as a shared genetic risk,29 enduring and additive cardiovascular damage imparted by each 
preeclampsia episode, or both. 
GH in the first pregnancy was not significantly associated with incident HF in this 
analysis, in contrast to findings reported by Behrens et al., who observed similar HF risks 
associated with GH and moderate preeclampsia.9 Although they did not meet the threshold for 
statistical significance in primary models, the hazards associated with GH plus SGA and/or 
preterm delivery, as well as the hazards associated with GH among one-child mothers, were 
similar to those associated with preeclampsia in the overall cohort. Given low absolute HF case 
counts (N=15) among women with GH in the first birth, low power may have hindered our 
ability to detect significant associations between GH and HF. 
 Our findings should be interpreted in the context of study design. First, although the 
CVDNOR Project captures nationwide Norwegian data, diagnoses are ascertained based on 
inpatient codes and the national death registry; thus, HF cases that were evaluated and managed 
exclusively in the outpatient setting (i.e., milder HF presentations) may not be captured. Prior 
work suggests that administrative codes yield high specificity but limited sensitivity for HF.30 
Second, due to low absolute risks and low overall HF case counts in our relatively young cohort, 
we were unable to test effect modification by preterm delivery and SGA delivery separately due 
to insufficient power and therefore assessed SGA and/or preterm delivery as a lumped effect-
modifier. Third, we were unable to ascertain development of cardiometabolic risk factors in the 
interval between the last birth and development of HF. Fourth, given lack of racial/ethnic 
diversity, whether findings in this white northern European cohort extend to non-white 



















    
    
    
    
    

































    
    
    
    
    












 Women with preeclampsia experienced two-fold risk of HF, without evidence of effect 
modification by concurrent SGA and/or preterm delivery. Risks increased further in women with 
preeclampsia and only one lifetime birth and in women with recurrent preeclampsia. These risks 
were largely indepe   HDP  a a   CAD. F  a     
elucidate underlying mechanisms and define optimal cardiovascular disease prevention and 




















    
    
    
    
    











Acknowledgements: The authors thank Tomislav Dimoski at The Norwegian Institute of Public 
Health, Norway, for his contribution by developing the software necessary for obtaining data 
from Norwegian hospitals, conducting the data collection, and quality assurance of data in this 
project.  
 
Disclaimer: Data from the Norwegian Cause of Death Registry have been used in this 
publication. The interpretation and reporting of these data are the sole responsibility of the 
authors, and no endorsement by this registry should be inferred.  
 
Funding: This work was supported by a grant from the Massachusetts General Hospital 
C a  W  H a  H a  P a . T  a  a  a a   by the U.S. 
National Heart, Lung, and Blood Institute (T32HL094301-07 to M.C.H.; and R01HL142711, 
R01HL148565, and R01HL148050 to P.N.), Fondation Leducq (TNE-18CVD04 to P.N.), the 
Massachusetts General Hospital (Hassenfeld Award to P.N.), and the European Research 
Council (ERC Advanced Grant 833076 to K.K.). 
 
Conflict of interest: P.N. reports grant support from Amgen, Apple, and Boston Scientific, as 
well as consulting income from Apple, all unrelated to this work. All remaining authors have no 




















    
    
    
    
    












1. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, 
Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating 
angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350(7):672-83. 
2. LifeCycle Project-Maternal Obesity and Childhood Outcomes Study Group, Voerman E, 
Santos S, Inskip H, Amiano P, Barros H, Charles MA, Chatzi L, Chrousos GP, Corpeleijn E, 
Crozier S, Doyon M, Eggesbø M, Fantini MP, Farchi S, Forastiere F, Georgiu V, Gori D, Hanke 
W, Hertz-Picciotto I, Heude B, Hivert MF, Hryhorczuk D, Iñiguez C, Karvonen AM, Küpers 
LK, Lagström H, Lawlor DA, Lehmann I, Magnus P, Majewska R, Mäkelä J, Manios Y, 
Mommers M, Morgen CS, Moschonis G, Nohr EA, Nybo Andersen AM, Oken E, Pac A, 
Papadopoulou E, Pekkanen J, Pizzi C, Polanska K, Porta D, Richiardi L, Rifas-Shiman SL, 
Roeleveld N, Ronfani L, Santos AC, Standl M, Stigum H, Stoltenberg C, Thiering E, Thijs C, 
Torrent M, Trnovec T, van Gelder MMHJ, van Rossem L, von Berg A, Vrijheid M, Wijga A, 
Zvinchuk O, Sørensen TIA, Godfrey K, Jaddoe VWV, Gaillard R. Association of Gestational 
Weight Gain With Adverse Maternal and Infant Outcomes. JAMA. 2019;321(17):1702-15. 
3. Wu P, Haththotuwa R, Kwok CS, Babu A, Kotronias RA, Rushton C, Zaman A, Fryer 
AA, Kadam U, Chew-Graham CA, Mamas MA. Preeclampsia and Future Cardiovascular 
Health: A Systematic Review and Meta-Analysis. Circ Cardiovasc Qual Outcomes. 2017;10(2). 
4. Leon LJ, McCarthy FP, Direk K, Gonzalez-Izquierdo A, Prieto-Merino D, Casas JP, 
Chappell L. Preeclampsia and Cardiovascular Disease in a Large UK Pregnancy Cohort of 



















    
    
    
    
    











5. Männistö T, Mendola P, Vääräsmäki M, Järvelin MR, Hartikainen AL, Pouta A, Suvanto 
E. Elevated blood pressure in pregnancy and subsequent chronic disease risk. Circulation. 
2013;127(6):681-90. 
6. Riise HKR, Sulo G, Tell GS, Igland J, Nygård O, Iversen AC, Daltveit AK. Association 
Between Gestational Hypertension and Risk of Cardiovascular Disease Among 617 589 
Norwegian Women. J Am Heart Assoc. 2018;7(10). 
7. Honigberg MC, Zekavat SM, Aragam K, Klarin D, Bhatt DL, Scott NS, Peloso GM, 
Natarajan P. Long-Term Cardiovascular Risk in Women With Hypertension During Pregnancy. J 
Am Coll Cardiol. 2019;74(22):2743-54. 
8. Haug EB, Horn J, Markovitz AR, Fraser A, Klykken B, Dalen H, Vatten LJ, Romundstad 
PR, Rich-Edwards JW, Asvold BO. Association of Conventional Cardiovascular Risk Factors 
With Cardiovascular Disease After Hypertensive Disorders of Pregnancy: Analysis of the Nord-
Trøndelag Health Study. JAMA Cardiol. 2019;4(7):628-35. 
9. Behrens I, Basit S, Lykke JA, Ranthe MF, Wohlfahrt J, Bundgaard H, Melbye M, Boyd 
HA. Association Between Hypertensive Disorders of Pregnancy and Later Risk of 
Cardiomyopathy. JAMA. 2016;315(10):1026-33. 
10. Honigberg MC, Givertz MM. Peripartum cardiomyopathy. BMJ. 2019;364:k5287. 
11. Tanz LJ, Stuart JJ, Williams PL, Rimm EB, Missmer SA, Rexrode KM, Rich-Edwards 
JW. Preterm Delivery and Maternal Cardiovascular Disease in Young and Middle-Aged Adult 
Women. Circulation. 2017;135(6):578-89. 
12. Grandi SM, Filion KB, Yoon S, Ayele HT, Doyle CM, Hutcheon JA, Smith GN, Gore 
GC, Ray JG, Nerenberg K, Platt RW. Cardiovascular Disease-Related Morbidity and Mortality 



















    
    
    
    
    











13. Riise HK, Sulo G, Tell GS, Igland J, Nygård O, Vollset SE, Iversen AC, Austgulen R, 
Daltveit AK. Incident Coronary Heart Disease After Preeclampsia: Role of Reduced Fetal 
Growth, Preterm Delivery, and Parity. J Am Heart Assoc. 2017;6(3). 
14. Brouwers L, van der Meiden-van Roest AJ, Savelkoul C, Vogelvang TE, Lely AT, Franx 
A, van Rijn BB. Recurrence of pre-eclampsia and the risk of future hypertension and 
cardiovascular disease: a systematic review and meta-analysis. BJOG. 2018;125(13):1642-54. 
15. Irgens LM. The Medical Birth Registry of Norway. Epidemiological research and 
surveillance throughout 30 years. Acta Obstet Gynecol Scand. 2000;79(6):435-9. 
16. Burton GJ, Redman CW, Roberts JM, Moffett A. Pre-eclampsia: pathophysiology and 
clinical implications. BMJ. 2019;366:l2381. 
17. Thomsen LC, Klungsøyr K, Roten LT, Tappert C, Araya E, Baerheim G, Tollaksen K, 
Fenstad MH, Macsali F, Austgulen R, Bjørge L. Validity of the diagnosis of pre-eclampsia in the 
Medical Birth Registry of Norway. Acta Obstet Gynecol Scand. 2013;92(8):943-50. 
18. Klungsøyr K, Harmon QE, Skard LB, Simonsen I, Austvoll ET, Alsaker ER, Starling A, 
Trogstad L, Magnus P, Engel SM. Validity of pre-eclampsia registration in the medical birth 
registry of norway for women participating in the Norwegian mother and child cohort study, 
1999-2010. Paediatr Perinat Epidemiol. 2014;28(5):362-71. 
19. Skjaerven R, Gjessing HK, Bakketeig LS. Birthweight by gestational age in Norway. 
Acta Obstet Gynecol Scand. 2000;79(6):440-9. 
20. Sulo G, Igland J, Vollset SE, Nygard O, Oyen N, Tell GS. Cardiovascular disease and 
diabetes mellitus in Norway during 1994-2009: CVDNOR  a nationwide research project. 



















    
    
    
    
    











21. Sulo G, Igland J, Nygård O, Vollset SE, Ebbing M, Tell GS. Favourable trends in 
incidence of AMI in Norway during 2001-2009 do not include younger adults: a CVDNOR 
project. Eur J Prev Cardiol. 2014;21(11):1358-64. 
22. Skjaerven R, Wilcox AJ, Klungsøyr K, Irgens LM, Vikse BE, Vatten LJ, Lie RT. 
Cardiovascular mortality after pre-eclampsia in one child mothers: prospective, population based 
cohort study. BMJ. 2012;345:e7677. 
23. Peters SA, Woodward M. Women's reproductive factors and incident cardiovascular 
disease in the UK Biobank. Heart. 2018;104(13):1069-75. 
24. Lv H, Wu H, Yin J, Qian J, Ge J. Parity and Cardiovascular Disease Mortality: a Dose-
Response Meta-Analysis of Cohort Studies. Sci Rep. 2015;5:13411. 
25. Li W, Ruan W, Lu Z, Wang D. Parity and risk of maternal cardiovascular disease: A 
dose-response meta-analysis of cohort studies. Eur J Prev Cardiol. 2019;26(6):592-602. 
26. Halland F, Morken NH, DeRoo LA, Klungsøyr K, Wilcox AJ, Skjærven R. Association 
of Women's Reproductive History With Long-term Mortality and Effect of Socioeconomic 
Factors. Obstet Gynecol. 2015;126(6):1181-7. 
27. Lykke JA, Langhoff-Roos J, Sibai BM, Funai EF, Triche EW, Paidas MJ. Hypertensive 
pregnancy disorders and subsequent cardiovascular morbidity and type 2 diabetes mellitus in the 
mother. Hypertension. 2009;53(6):944-51. 
28. Auger N, Fraser WD, Schnitzer M, Leduc L, Healy-Profitós J, Paradis G. Recurrent pre-
eclampsia and subsequent cardiovascular risk. Heart. 2017;103(3):235-43. 
29. Gammill HS, Chettier R, Brewer A, Roberts JM, Shree R, Tsigas E, Ward K. 



















    
    
    
    
    











30. McCormick N, Lacaille D, Bhole V, Avina-Zubieta JA. Validity of heart failure 





















    
    
    
    
    











Novelty and Significance 
 
What Is New? 
x Compared to women without hypertensive disorders of pregnancy (HDP), women with 
preeclampsia had two-fold risk of future heart failure. Risk of heart failure was not 
modified by concurrent small-for-gestational age and/or preterm birth.  
x Women with a single lifetime birth complicated by preeclampsia and women with 
recurrent preeclampsia demonstrated further elevation in heart failure risk.  
x H a  a    a    HDP  a a   a  a  
disease. 
 
What Is Relevant? 
x The hypertensive disorders of pregnancy (e.g., gestational hypertension, preeclampsia) 




x Women with preeclampsia experienced two-fold risk of HF, without evidence of effect 
modification by concurrent SGA and/or preterm delivery. Risks increased further in 
women whose only lifetime birth was complicated by preeclampsia and in women with 



















    
    
    
    
    













Figure 1. Creation of the study cohort. 
 
Figure 2. Kaplan-Meier curves for heart failure-free survival by hypertensive disorder of 
pregnancy status in the first birth. 
HDP = hypertensive disorder of pregnancy; GH = gestational hypertension; PE = preeclampsia 
Mean (SD) maternal age at the start of follow-up is 30.3 (4.8) years for women with no HDP, 
30.8 (4.7) years for women with gestational hypertension, and 30.3 (4.8) years for preeclampsia 
in the first pregnancy 
 
Figure 3. Kaplan-Meier curves for heart failure-free survival (A) by hypertensive disorder of 
pregnancy status among one-child mothers and (B) by recurrent hypertensive disorder of 
a  a  a    2  b . 
HDP = hypertensive disorder of pregnancy; GH = gestational hypertension; PE = preeclampsia 
Mean (SD) maternal age at the start of follow-up is 27.6 (5.8) years for one-child mothers with 
no HDP, 29.0 (5.9) years for one-child mothers with GH, 28.1 (5.9) years for one-child mothers 
 PE, 30.8 (4.4) a     2 b  a   HDP, 31.5 (4.4) a     
GH  1 b  a   PE, 31.1 (4.4) a     2 b rths and 1 PE episode, and 31.5 




















    
    
    
    
    











Table 1. Baseline characteristics and outcomes of study subjects by hypertensive disorder 





(n = 475,269) 
Gestational 
hypertension  
(n = 8,827) 
Preeclampsia  
(n = 24,326) 
Maternal age at first 
birth, y 
25.5 (4.7) 26.3 (4.8) 25.7 (4.8) 
Married/co-habitant 
during first pregnancy 
393,084 (82.7%) 7,646 (86.6%) 20,645 (84.9%) 
Chronic diabetes 
diagnosis prior to first 
birth 
1,495 (0.3%) 62 (0.7%) 369 (1.5%) 
Preterm delivery in 
first birth 
25,996 (5.5%) 609 (6.9%) 4,910 (20.2%) 
Small-for-gestational 
age delivery in first 
birth 
57,601 (12.1%) 1,471 (16.7%) 5,846 (24.0%) 
Final parity during the 
study period, median 
(IQR) 
2 (2,3) 2 (2,3) 2 (2,3) 
Among participants 
with 2 pregnancies, 
12,931 / 395,122 
(3.3%) 
1,760 / 7,155  
(24.6%) 




















    
    
    
    
    











HDP in second or 
subsequent 
pregnancy, n/N (%) 
Maternal age at last 
birth, y 
30.3 (4.8) 30.7 (4.7) 30.3 (4.8) 
Time from last birth 
to censoring, y 
12.4 (7.2) 13.0 (7.6) 11.7 (7.1) 
Chronic diabetes 
diagnosed prior to last 
birth 
2,269 (0.5%) 101 (1.1%) 463 (1.9%) 
Chronic hypertension 
diagnosed prior to last 
birth 
1,108 (0.2%) 266 (3.0%) 439 (1.8%) 
Incident coronary 
artery disease during 
follow-up 





499 (0.1%) 15 (0.2%) 51 (0.2%) 
Among women with 
heart failure, incident 
coronary artery 



















    
    
    
    
    

































    
    
    
    
    











Table 2. Hazard ratios for heart failure* by pregnancy complications in the first birth. 




















By hypertensive disorder of pregnancy status only 
No HDP 475,269 499 / 5,883,782 Reference Reference 

















By hypertensive disorder of pregnancy, small-for-gestational age delivery, and preterm delivery 
status 
No HDP 475,269 499 / 5,883,782 Reference Reference 























    
    
    
    
    











HDP with preterm 
and/or SGA delivery§ 













hypertension with SGA 
and/or preterm birth 










Preeclampsia with SGA 
and/or preterm birth 





*Heart failure endpoint is a composite of heart-failure related hospitalization and heart failure-
related death 
Age-adjusted models are adjusted only for maternal age at the last birth 
Fully adjusted models are adjusted for maternal birth year, maternal age at first birth, maternal 
age at last birth, chronic diabetes diagnosis prior to last birth, and final party 
§HDP includes both gestational hypertension and preeclampsia 



















    
    
    
    
    











Table 3. Hazard ratios (95% confidence intervals) for heart failure* by hypertensive 
disorder of pregnancy status in the first and subsequent births. 
HDP status in 
first birth 


































hypertension but no 
pr eclampsia in later 
births 








Preeclampsia in later 
births 


























    
    
    
    
    











hypertension (0.62-2.78) (0.64-2.84) 
Gestational 
hypertension 







HDP in second 
and/or later births 


















HDP in second 
and/or later births 







*Heart failure endpoint is a composite of heart-failure related hospitalization and heart failure-
related death 
Age-adjusted models are adjusted only for maternal age at the last birth 
Fully adjusted models are adjusted for maternal birth year, maternal age at first birth, maternal 
age at last birth, and chronic diabetes diagnosis prior to last birth 
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